menu toggle

Global market access consulting

Transforming evidence and market intelligence into effective global market access strategies and solutions. 

Global market access capabilities

Unlock your product potential with a global market access partner: 

  • Engage - early with stakeholders
  • Monitor - global and local Health Technology (HTA) landscape
  • Design - strong evidence and submission packages
  • Leverage - opportunities for HTA interactions & generate real-world evidence
  • Communicate - your product's value
  • Apply - critical health economics and outcomes research information

Our global biopharma consulting capabilities

When launching products in Europe and HTA countries, AmerisourceBergen provides deep understanding of the environment, competition, and considerations for market access. We evaluate how your product many be viewed by payers and assess what may be needed beyond your clinical trials. We can help you engage early with key decision-makers and provide timely advice on strategy and execution.

Health economics & outcomes research

Work with industry-recognized experts who apply scientific methodologies to conduct the full scope of health economics and outcomes research for effective strategic planning. We combine rigorous, technical expertise with an understanding of local markets and multiple disease states to deliver relevant, transparent, and credible results to help inform practical strategies and tactics that communicate a robust portfolio of value-based evidence.

Market access consulting

When launching products outside the U.S., Xcenda provides deep understanding of the environment, competition, and considerations for market access across Europe and HTA countries. We evaluate how your product many be viewed by payers and assess what may be needed beyond your clinical trials. 

Real-world evidence

With strategic global data partnerships in the US, Germany, the UK, the Netherlands, France, Sweden, Canada, Japan, and China, we support our clients' global strategies along the entire product lifecycle.

Our databases are sourced from administrative claims, electronic medical records, or disease registries, and capture patient-level health information and outcomes for healthcare services performed in various care settings.

PharmaLex Acquisition

In the News

AmerisourceBergen completes acquisition of PharmaLex in January 2023

The acquisition of PharmaLex enhances AmerisourceBergen’s growth strategy by advancing its leadership in specialty services and global platform of pharma manufacturer services capabilities. PharmaLex’s regulatory affairs, development consulting and scientific affairs, pharmacovigilance, and quality management and compliance services expand AmerisourceBergen’s role as partner of choice for biopharmaceutical partners across the pharmaceutical development and commercialization journey. 
Map of Europe

Ask local experts from markets worldwide

Global market access network

Understand the nuances of key international markets through Xcenda's Global Market Access Network. This proprietary panel of advisors is composed of healthcare and payer experts who have the experience, insight, and relationships to help with formal documentation, evidentiary demands, and all aspects of the complex submission processes in more than 22 countries around the world.

Our global market access and consulting insights

New pan-EU HTA: How can biopharma navigate the joint clinical assessment?

The new European Union (EU) Health Technology Assessment (HTA) regulation was enacted in January 2022 with the primary objective of streamlining the clinical assessment process for EU member states' HTA bodies. Biopharma companies need to be aware of the clinical development and market access processes in this uncharted environment. Enter your information below to read about how biopharma can approach their planning more successfully.

Three questions to ask about your market access partner

The new 2022 European Union (EU) health technology assessment (HTA) regulation is intended to streamline assessment of clinical data across the EU and minimize duplication of effort, for both health technology developers and HTA bodies. We consider what the new regulation means for health technology developers, particularly in terms of evidence submission requirements and what can be done to influence the implementation of the new regulation.

The new EU regulation on health technology assessment: Major change or minor adjustment?

Taking into account different comparator products, HTA methodologies and policy questions in individual member states and the need for submission of country-specific economic evidence, we consider what the new 2022 European Union (EU) health technology assessment (HTA) regulation means for health technology developers, particularly in terms of evidence submission requirements and what can be done to influence the implementation of the new regulation.

subscribe to HTA quarterly

HTA Quarterly

Each edition of HTA Quarterly provides insights and analysis from global experts with local market expertise on key priorities and perspectives affecting HTA. From therapeutic area spotlights to geographic reviews to critical industry topics, keep current on HTA activity around the globe with HTA Quarterly. Browse the archive and subscribe to the quarterly newsletter today. 
biopharma commercialization

Biopharma Services

Each investment we make is focused on connecting healthcare stakeholders to accelerate healthier futures. Our unrivaled expertise powers us in our vision to help you fully realize your product’s power—through the patients it reaches and the strategic outcomes it delivers. Learn more about our end to end suite of commercialization solutions for biopharma companies.

Let's work together to envision new paths to healthier futures around the world.

Start a conversation

Navigating market access in a global marketplace can be overwhelming. Our team of international market access consultants are here to help work with you through your next launch.